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Introduction
Esophageal cancer is a highly virulent malignancy,
where the overall cure rate is <10%. At presentation,
systemic disease is found in over 50% of the cases, leading
to incurability. Of the patients that present with loco-
regional disease, most will relapse with the primary therapy,
leaving the cure rate in this group to 12-35%.1-3 The most
commonly accepted standard of care for localized disease is
surgical resection. Neoadjuvant chemoradiotherapy given
as a combined modality therapy leads to pathological
responses to 20-40%, which could be the surrogate markers
to cure. Newer agents and targeted therapies will have an
important role in the care of esophageal cancer.
Epidemiology
World wide, esophageal cancer is the fourth most
common malignancy, after gastric, colorectal and
hepatocelluar malignancies. It is the 10th most common
malignancy (3.9%), but is the 6th leading cause of cancer
death (5.9%). World over, 316,000 new cases are diagnosed
each year, of which 286,000 die. In the USA, the cure rate
does not appear to be any better. Each year 13,000 new
cases are diagnosed, of which 12,600 will die.1-3 Data from
Karachi showed that it is the 7th most common malignancy
in men and 6th most common malignancy in females.4 At
AKUH, this was the 10th most common in men (5%)5,
while at Cenar, Quetta, this was the 3rd most common
malignancy in men, accounting for 11% of all cancers seen.6
This uneven distribution is at least partly because Cenar has
radiation therapy, where referrals would be higher. This may
also suggest that perhaps there are higher cases of
esophageal cancer in that part of Pakistan as compared to
Karachi, owing to the meeting of the border of Baluchistan
with Iran and Afghanistan, parts of where this disease is
endemic. However definitive epidemiological data is
lacking. While in the West, adenocarcinoma is the most
prevalent histology, world over, including Pakistan;
squamous cell carcinoma is the predominant histology.1,2,7
The incidence is as high as 100/100,000 cases in some parts
of the world, including parts of Iran, China and USSR.
South East Asia has intermediate probability of about 10-
50/100,000, and the West, including the USA has low
incidence of about <10/100,000.1,2
The median age at presentation in our country is 55
years. Male: female ratio is 1.2:1. Lower esophageal
cancers account for 44-60% of cases, mid esophagus 30-
54% and upper esophagus 10-25%.
Risk Factors
Tobacco use is strongly associated with esophageal
cancer. In one study, 78% of all cases were tobacco users.
Niswar and betel nut use is also implicated as a risk factor.
It is known that smoking increases the risk of developing
squamous cell carcinoma of the esophagus by 5-10 folds,
and of developing adenocarcinoma by 2 fold. Molecular
changes, including p53 mutation with smoking heralds the
development of malignancy. Alcohol has additive and
perhaps synergistic effect, where the risk increases to as
high as 100 folds.8-11 The raise in the adenocarcinoma of the
esophagus in the West may be attributable to the raise in the
prevalence of Barrett's Esophagus, a well-recognized risk
factor. This may be related to Helicobacter Pylori infection,
the incidence of which is decreasing, leading to less
atrophic gastritis and higher gastroesophageal reflux
disease.12,13 About 1-3% of these patients with Barrett's
Esophagus will develop adenocarcinoma, 3% will develop
high grade dysplasia, and 15% low grade dysplasia.14,15
Determining flow cytometric and molecular studies in
patients with Barrett's and dysplasia appear useful to
indicate which patients will develop invasive
malignancy.16,17 However, this needs more studies before
becoming a standard part of surveillance endoscopy. The
American Society of Gastroenterology guidelines for
surveillance endoscopy in patients with Barrett's Esophagus
calls for endoscopic evaluation every 3-5 years in patients
with no dysplasia and every 6-12 months in patients with
low grade dysplasia. For patients with high-grade dysplasia,
options include intensive surveillance done every 3 months,
ablative therapy or esophagectomy.18
Molecular Analysis
The unfavorable biology of patients with esophageal
cancers explains at least partly why these patients do poorly.
Targeted therapies against these molecular anomalies show
promise in the future of this malignancy. Like any other
malignancy, over expression of protooncogenes and
suppression of tumor suppressor genes will lead to
esophageal cancer. Recognized oncogenes include
Epidermal Growth Factor Receptors, Cyclin D1 and
Telomerase. Tumor suppressor genes implicated in this
malignancy include Rb gene, p53, p16, and 3p (FHIT).  The
cell cycle progression requires that the growth factors be
activated, resulting in the expression and binding of Cyclins
and Cyclin Dependent Kinases (CDK). This leads the cell to
move from G1 to S to G2 and then to M phase where the
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cell finally divides. Cyclin D-CDK 4/6 complexes result in
the phosphorylation of RB gene product that then cannot
bind to and inhibit the Transcription factors. The cycle
moves on to the S phase where more Cyclin/CDK
complexes cause the cells to go forward.19,20 
Tumor suppressor gene p53 product regulates cell-
cycle progression, DNA repair, apoptosis and
neovascularization. It also inhibits the vascular endothelial
growth factor. Approximately 50-80% of esophageal
cancers express p53 mutation; here it correlates with
disease-free and overall survival. P53 mutation is also an
early event in the development of dysplasia.21-24 Epidermal
Growth Factor Receptor is a 170-kD tyrosine kinase
receptor, activation of which results in overexpression of
Cyclins and CDKs. Overexpression is more commonly seen
in squamous cell carcinoma and confers unfavorable
prognosis.25-27 Overexpression of Cyclin D1 protooncogene
is seen in 40-60% of esophageal cancer and is more
commonly associated with advanced stage, leading to
diminish overall survival. Mutations in Rb and p16 genes
are seen in 20-60% of esophageal cancer and again, results
in poor prognosis.28-32 Telomerase synthesizes telomeres,
which are DNA sequences found at the ends of
chromosomes, that then protects the chromosomes from
recombination, nuclease attacks, activation of cell-cycle
check point, and end-to-end fusion. All these functions of
Table 1. Early disease: treatment results - adjuvant setting.
Group of Treatment  arms Radiotherapy Chemotherapy No. of Results
institution patients
Japanese Esophageal Operation+cisplatin and 50 Gy Cisplatin 258 No significant difference in
Oncology Group43 vindesine/operation + vindesine survival up to 5 years in the
radiotherapy 2 groups (44% vs. 42%)
Japanese Esophageal Operation + adjuvant None Cisplatin 205 Adjuvant chemotherapy using
Oncology Group44 chemotherapy cisplatin and vindesine has
no additive effect on survival
in patients with esophageal
cancer compared to surgery
alone
Japan Clinical Oncology Operation + adjuvant None Cisplatin 205 The 5-year survival was 44.9%
Group45 chemotherapy vindesine in the surgery alone group
and 48.1% in the surgery
plus chemotherapy group
French University Operation + 45 to 55 Gy None 221 Postoperative radiation therapy
Association for did not improve survival. The
Surgical Research46 recurrence rate was lower in
patients receiving radiation
therapy as compared with those
with surgery alone
University of Hong Kong, Operation + 49 Gy after None 130 The overall median survival
Queen Mary Hospital47 radiotherapy curative resection of patients after postoperative
and 52.5 Grays radiotherapy was 8.7 months,
which was shorter than the
15.2 months for the control
groups (p = 0.02).
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telomeres will protect the malignant cells from breakdown.
Overexpression of telomerase is seen in many malignancies
including esophageal cancer. 33-36
Staging and Survival
In one local study, virtually all patients presented with
stages III and IV. Dysphagia and loss of weight are found
in 93% and 75% of cases respectively. Other symptoms
include anorexia, chest pains and GI bleed. Median
duration of symptoms is 3-4 months. 
The anatomical location accounts for two
unfavorable features resulting in poor survival. Firstly,
esophagus has an indistinct serosa. Secondly, this organ has
a unique lymphatic anatomy. Much unlike the other GI
Table 2. Early disease: treatment results - neoadjuvant setting.
Group or Treatment arms Radiotherapy Chemotherapy No. of Results
institution patients
Regional Cancer Operation + 20 Gy 5-FU 86 Long term survival was not
Institute, Centre preoperative Cisplatin significantly different, with 47%
Eugene Marquis48 chemotherapy of both groups with squamous cell
carcinoma of the esophagus
alive at 1 year
University of Operation + 45 Gy Cisplatin 100 The two groups did not demonstrate
Michigan Medical preoperative 5-FU a statistically significant survival
Center49 chemoradiation vinblastine difference
University Hospital Operation + 18.5 Gy Cisplatin 297 Preoperative chemoradiotherapy
J. Minjoz, preoperative did not improve overall survival,
Besancon, France50 chemoradiation but it did prolong disease-free
survival and survival free of 
local disease. The median
survival was 18.6 months for
both groups.
St. James’s Operation + 40 Gy Fluorouracil 102 The median survival of patients
Hospital, Dublin, preoperative cisplatin assigned to multimodal therapy
Ireland51 was 16 months, as compared with
11 months for those assigned to
surgery alone (p = 0.01)
Memorial Sloan- Operation + None Fluorouracil 440 After 55.4 months, there were no
Kettering Cancer, preoperative cisplatin significant differences between
New York53 the two groups in median survival:
14.9 months for the preoperative
chemotherapy and 16.1 months
for the surgery only group
(p = 0.53)
UK Medial Operation + Fluorouracil 802 In patients with resectable esophageal
Research Council preoperative cisplatin cancer, two cycles of pre-operative
Upper GI Tract chemotherapy cisplatin and fluorouracil improved
Cancer Group54 survival without incurring additional
serious adverse events. Median
survival was 17.2 months compared
with 13.3 months (difference 3.9
months; 95% CI 1.1-6.9 months)
Radiation Combined 50 Gy Fluorouracil Combined therapy increases the
Therapy chemoradio- cisplatin survival of patients who have
Oncology Group55 therapy and squamous cell or adenocarcinoma
of the esophagus, T1-3 NO-1 MO,
compared with RT alone
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organs, lymphatic channels in the esophagus are present in
the submucosa, just below the muscularis mucosa.
Therefore, the probability of lymph node metastasis in the
submucosal invasive malignancy is as high as 25%. A T2
lesion has a 50% chance of lymphatic spread. This is the
reason, why all but the most superficial esophageal
malignancies should be considered a systemic disease.37-39
Patients with dysplasia and Stage I disease involving
the mucosa have a cure rate of >80%. However, all other
esophageal cancer patients have a cure rate of <50%. Even
the Stage I disease involving the submucosa have a cure rate
40-50%. Regional lymph node involvement results in cure
rate of <25%.37,38 
Treatment of Early Disease
Esophagectomy is the most commonly accepted
standard of care for loco-regional disease. Whether a
transthoracic approach is undertaken, or a transhiatal
esophagectomy is performed, the results are dismal, as the
recurrences are high. The overall cure rate with surgery
alone is 12-25%. Surgical mortality is less than 10% and the
results are the same whether the histology is
adenocarcinoma or squamous cell carcinoma.40-42 The
Japanese Oncology Group performed three randomized
trials in the adjuvant setting. No benefit was seen when
radiation therapy was compared with Cisplatin/Vindescine
chemotherapy. Again, in the second trial, no benefit was
seen when surgery alone was compared with postoperative
Cisplatin/Vindescine in node positive patients. In the third
study, surgery alone was compared with postoperative
Cisplatin/5FU for 2 cycles; there was trend toward
improvement in disease free survival in patients with node
positive disease.43-45 This suggests that adjuvant
chemotherapy might be useful in node positive patients,
however 2 cycles may not be enough. Two studies defining
the role of the adjuvant radiation therapy showed no benefit
in improving survival.46,47
Preoperative chemoradiotherapy in improving the
cure rate has been studied. Unfortunately the data is not
very impressive. There are four randomized studies
comparing preoperative chemoradiotherapy followed by
surgery vs. surgery alone.48-51 Three of the four studies are
underpowered. Only one study is positive in patients with
adenocarcinoma of the esophagus; however the controls
with surgery alone had a poor survival of 6% only.51
Another criticism that this study had was that CT scan was
not mandated for staging. The randomized multimodality
therapy on squamous cell carcinoma was negative.50
However, their use of chemotherapy was sub optimal. What
is required is a large randomized, multicenter study testing
Table 3. Metastatic disease - treatment results.
Group or Treatment arms Radiotherapy Chemotherapy No. of Results
institution patients
Institut  J. Cisplatin + 5-FU None Cisplatin + 88 The response rate was 35% and 19% and the
Bordet, Brussels, 5-FU median duration of survival was 33 weeks
Belgium57 and 28 weeks for Cis+5-FU and cisplatin 
only groups, respectively. Seven treatment
related deaths (16%) were observed in the
combination therapy group and none in
the 5-FU group.
University of Paclitaxel None Paclitaxel 52 At a median follow-up of 9 months,
Texas M.D. No control 32 patients remain alive, with an
Anderson Cancer actuarial median survival duration
Center58 of 13.2 months.
The Eastern Docetaxel None Docetaxel 41 An objective response rate of 17%
Cooperative No control (90% confidence interval [CI], 8%
Oncology Group group to 30% was observed. The most common
(ECOG)59 toxicity was grade 4 neutropenia, which
occurred in 88% of patients.
Peter Enzinger, None CPT-11 38 Objective response rate was 15% (95% CI, 2 to 27%).
Mathew Kulke CPT-11 has activity in advance 1 and gastric
et al.60 adenocarcinoma although toxicity
must be monitored closely in this
patient population
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preoperative chemoradiotherapy with surgery alone. Such a
study was initialed by the Intergroup, but was closed
because of poor accrual. The reason is physician-bias;
despite lack of concrete evidence over 50% of the
oncologists in the USA will treat the limited disease with
chemoradiotherapy followed by surgery.52
Two large randomized trials in preoperative
chemotherapy setting deserve attention. Both these studies
compared surgery with preoperative chemotherapy with
5FU/Cisplatin followed by surgery. The RTOG study
showed no improvement with addition of chemotherapy. 53
The MRC study, which is almost twice as large, is showing
a four-year projected survival favoring chemotherapy arm.
However, the follow-up so far is short, staging CT scan was
optional, and the surgical procedure was not standardized . 54
Many randomized trials testing preoperative radiation
therapy did not show benefit with addition of radiation
therapy to surgery.
Those patients with localized disease who are poor
candidates for surgery should be treated with combined
chemoradiotherapy, which is superior to radiotherapy alone.
Five-year survival in one pivotal study was 26% with
chemoradiotherapy vs. 0% with radiotherapy alone. 55
Metastatic Disease
One study showed that nearly all cases here are
Stages III or IV disease. The most common modality of
treatment in that study is radiation therapy with or without
Cisplatin based chemotherapy.
Nearly half the patients with esophageal cancer in
the West present with disseminated disease. Treatment of
advanced disease is largely with chemotherapy. Single
agents have a response rate of 20-30%56, while combination
chemotherapy respond better, with response rates of 44-
55%. Cisplatin/5FU continues to be a commonly used
combination chemotherapy.57 Newer agents are active in
this disease. Agents like Taxanes, a microtubule inhibitor,
and Irinotecan, a Topo-isomerase I inhibitor, are particularly
active. Both these agents can be used singly or in
combination with Cisplatin.  Primary endpoint in treatment
of metastatic disease is improvement of quality of life in
face of acceptable toxicity profile. Subjective relief of
dysphagia is seen in 80-90% of cases with these newer
combination chemotherapies.58-61
Targeted therapies are being actively tested in
malignancies, including esophageal cancer. Anti-Epidermal
Growth Factor Receptors show synergy with both
chemotherapy and radiation therapy, and has had responses
in head and neck, colorectal and lung cancers.62-64 A study
looking at one such agent, Cetuximab (C-225), in
combination with chemoradiotherapy is planned in
esophageal cancer. 
Conclusion
Esophageal Cancer is a challenge to treat for
oncologists. Firstly, over 50% of these patients present as
advanced disease, and hence are incurable. Secondly, early
disease, despite definitive treatment, tends to recur. This is
largely due to unfavorable biology and anatomical
constraints. The most widely used standard of treatment for
early disease is surgical resection. Larger trials are required
to answer the role of addition chemotherapy and radiation
therapy to surgery in localized disease. Newer
chemotherapy and targeted therapy including the anti-
epidermal growth factor receptors will continue to impact
and define the optimum treatment of this very lethal
malignancy.  
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